CFO and CEO of Rare Lung Disease Treatment Company Cash Out Hundreds of Millions After Exercising Stock Options

At the end of March, United Therapeutics Corp. (NASDAQ: UTHR) CFO James Edgemon and CEO Martin Rossblatt disclosed that they exercised stock options and sold a portion of their holdings on the open market. On March 26, Edgemon exercised options on 10,000 shares, acquired the same number of common shares, and immediately sold them at approximately $532–$540 per share, netting about $5.4 million (roughly ₩70 billion). He later reported holding around 19,000 shares. On March 30, Rossblatt exercised options on 9,500 shares and sold them at around $582–$603 per share, realizing a similar gain. That same day, the company announced that its idiopathic pulmonary fibrosis treatment candidate, the Tyvaso inhalation solution, met the primary endpoint in the TETON-1 Phase III trial and plans to file an FDA application for an idiopathic pulmonary fibrosis indication by this summer.

With its first-quarter 2026 earnings release scheduled for April 29, investors are focusing on United Therapeutics’ broader pipeline progress. Beyond Tyvaso, the company is advancing early diagnostic research in pulmonary arterial hypertension and has received a Regenerative Medicine Advanced Therapy (RMAT) designation for its miroliver ELAP liver-assist device. Insider trading flows have been mixed: other directors have executed small sales, while a legal affairs officer has made purchases.

Founded in 1996, United Therapeutics is a U.S. biotech firm specializing in therapies for severe rare pulmonary diseases—such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis—alongside organ transplant and xenotransplant technologies. The Tyvaso franchise remains its core revenue driver. Founder and CEO Martin Rossblatt, also known as a co-founder of satellite radio company SiriusXM, has long championed a public-benefit corporate model focused on rare-disease treatments and transplant innovations.